Form 6-K Altamira Therapeutics For: Jan 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Altamira Therapeutics (CYTO) Enters ATM Agreement
January 19, 2024 4:47 PM ESTOn January 19, 2024, Altamira Therapeutics (NASDAQ: CYTO) entered into an At the Market Offering Agreement (the Agreement) with H.C. Wainwright & Co., LLC (HCW), as sales agent or principal, relating to the offer and sale of the Companys common shares, par value $0.002 per share, from time to time, having an aggregate offering amount of up to $1.66 million (the Offering). On January 19, 2024, pursuant to the Agreement, the Company filed a prospectus supplement (the Prospectus Supplement), including an accompanying base prospectus, dated December 8, 2021, forming a part of its effective registration statement on Form F-3 (File No. 333-261127),... More
